Samantha Peacock is an associate in the London office of Latham & Watkins and a member of the firm’s Corporate Department.

Ms. Peacock advises on a broad range of corporate matters, including mergers and acquisitions, private equity, and venture capital investments. Ms. Peacock has particular expertise and interest in the life sciences sector.

Ms. Peacock trained in-house at pharmaceutical company Actavis (now part of the Teva group) where she gained a broad range of corporate and commercial experience. Her training included a six-month secondment to Latham's Corporate Department.

Ms. Peacock’s experience includes advising:

Venture Capital - Investor Side

  • Octopus Ventures on its investments into Vira Health, Automata, and Touchlab spanning from pre-seed to Series B
  • Hoxton Ventures on its lead investments in Skin Analytics, Bother, Slice, and Luminary ROLI
  • VEON Ventures on its strategic investments in the Series A and B rounds of into Bangladesh based ShopUp in and Series A round of Pakistan based Dastgyr
  • Novo on its Series D investment in Quanta Dialysis
  • Citi Ventures on its investment in GoHenry’s US$40 million funding round
  • GIC, JP Morgan, and HSBC’ Venture Capital Fund on their Series B+ investments in Miotech, an ESG data start up
  • HSBC Investment Bank on its Series B investments in Miotech, Callsign, and Silent Eight

Venture Capital - Company Side

  • WorldRemit on its US$292 million Series E funding round
  • Toqio on its seed funding round led by Seaya and Speedinvest
  • LifeScore on its £11m Series A financing led by Octopus Ventures and Warner Music Group
  • Aztec Network on its Series A funding round led by Paradigm
  • Fertifa Limited, the UK’s first and leading reproductive healthcare benefits provider and provider of a next-generation fertility clinic, on its seed funding round led by Passion Capital

Life Sciences and Healthcare

  • Norgine, a European specialty pharmaceutical company, on the sale of a controlling stake to Goldman Sachs Asset Management
  • Alliance Pharma on its acquisition of US scar treatment brand, ScarAway
  • Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with the US$703 million acquisition by CVC of women’s healthcare assets from Teva 
  • TLS Beta on the acquisition of a 30% stake in Stamford Devices, an Ireland-based provider of medical device and drug delivery services and holding company for Aerogen 
  • Actavis UK and Actavis Ireland on its £603 million divestment by Teva to Intas* 
  • Accelovance Inc on its cross-border acquisition of THERAMetrics Holding AG’s CRO subsidiaries in Italy, Germany, and Romania* 
  • Adorial on its acquisition by C4X Discovery Holdings plc*
  • Actavis on its £306 million acquisition of Auden Mckenzie, a pharmaceutical company specialising in the development, licensing and marketing of generic medicines and proprietary brands, making Actavis the largest generics company in the UK
  • Actavis on the divestment of part of its Western European generics sale and marketing business to Aurobindo*


  • CDPQ on its partnership with GIM and joint investment in FNZ, a deal valuing the company at £1.65 billion and being one of the world’s largest fintech transactions of 2018
  • Thomas Cook on the sale of its Belgium airline business to Brussels Airlines, a subsidiary of Lufthansa
  • H&F on the disposal of on the disposal of a minority interest in the Verisure Securitas Direct group to GIC
  • Mimecast on the acquisition of Simply Migrate, a London-based provider of archive data migration technology
  • Onex on its up to €3.75 billion acquisition of SIG Combibloc Group AG
  • Acano in connection with its US$700 million acquisition by Cisco*
  • Epicor Software Corporation in connection with its acquisition of Dot-Net-IT Limited*

*Matter handled prior to joining Latham

Bar Qualification

  • England and Wales (Solicitor)


  • Legal Practice Course, BPP Law School, London, 2014
  • LL.B. (Hons), King's College London, 2011